AAUM (Average Assets Under Management) of ₹94.08 Cr for Apr-Jun 2026 is the combined figure across Direct and Regular plans — sourced from AMFI India's quarterly disclosure. Equity Holdings above shows only the stock portion from the latest portfolio filing.
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 64.7% | 63.1% | ▼ -1.6% |
| Healthcare Services | 26.9% | 27.5% | ▲ +0.6% |
| Chemicals & Petrochemicals | 3.1% | 2.8% | ▼ -0.3% |
| Insurance | 1.0% | 0.9% | ▼ -0.1% |
| Retailing | 0.7% | 0.7% | ● +0.0% |
| IT - Services | 0.5% | 0.5% | ● +0.0% |
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 63.1% | 63.3% | ▲ +0.2% |
| Healthcare Services | 27.5% | 25.7% | ▼ -1.8% |
| Chemicals & Petrochemicals | 2.8% | 3.0% | ▲ +0.2% |
| Insurance | 0.9% | 1.4% | ▲ +0.5% |
| Retailing | 0.7% | 0.7% | ● +0.0% |
| IT - Services | 0.5% | 0.5% | ● 0.0% |
Comparing Jul 2026 → Aug 2026
| # | Stock | Sector | Weight (Aug 2026) |
|---|---|---|---|
| 1 | Gland Pharma Limited ₹91.62 L |
Pharmaceuticals & Biotechnology | 0.73% |
| 2 | IPCA Laboratories Limited ₹63.39 L |
Pharmaceuticals & Biotechnology | 0.51% |
| # | Stock | Sector | Jul 2026 | Aug 2026 | Change |
|---|---|---|---|---|---|
| 1 | Manipal Health Enterprises Ltd ₹5.16 Cr |
Healthcare Services | 0.96% | 4.12% | +3.16% |
| 2 | Dr.Agarwals Eye Hospital Limited ₹1.50 Cr |
Healthcare Services | 0.45% | 1.20% | +0.75% |
| 3 | ICICI Lombard General Insurance Company Limited ₹1.75 Cr |
Insurance | 0.89% | 1.40% | +0.51% |
| 4 | Divi's Laboratories Limited ₹13.57 Cr |
Pharmaceuticals & Biotechnology | 10.35% | 10.85% | +0.50% |
| 5 | Rubicon Research Limited ₹5.02 Cr |
Pharmaceuticals & Biotechnology | 3.68% | 4.01% | +0.33% |
| 6 | Neuland Laboratories Limited ₹4.08 Cr |
Pharmaceuticals & Biotechnology | 3.03% | 3.26% | +0.23% |
| 7 | Navin Fluorine International Limited ₹3.81 Cr |
Chemicals & Petrochemicals | 2.81% | 3.04% | +0.23% |
| 8 | Lupin Limited ₹1.78 Cr |
Pharmaceuticals & Biotechnology | 1.23% | 1.42% | +0.19% |
| 9 | Zydus Lifesciences Limited ₹1.89 Cr |
Pharmaceuticals & Biotechnology | 1.35% | 1.51% | +0.16% |
| 10 | Lenskart Solutions Limited ₹89.43 L |
Retailing | 0.68% | 0.71% | +0.03% |
| # | Stock | Sector | Jul 2026 | Aug 2026 | Change |
|---|---|---|---|---|---|
| 1 | Aster DM Healthcare Limited ₹3.62 Cr |
Healthcare Services | 6.21% | 2.89% | -3.32% |
| 2 | Max Healthcare Institute Limited ₹6.21 Cr |
Healthcare Services | 5.86% | 4.96% | -0.90% |
| 3 | Krishna Institute Of Medical Sciences Limited ₹3.95 Cr |
Healthcare Services | 3.77% | 3.15% | -0.62% |
| 4 | Mankind Pharma Limited ₹5.09 Cr |
Pharmaceuticals & Biotechnology | 4.66% | 4.07% | -0.59% |
| 5 | Torrent Pharmaceuticals Limited ₹11.09 Cr |
Pharmaceuticals & Biotechnology | 9.38% | 8.86% | -0.52% |
| 6 | Jupiter Life Line Hospitals Limited ₹2.22 Cr |
Healthcare Services | 2.23% | 1.77% | -0.46% |
| 7 | Abbott India Limited ₹3.54 Cr |
Pharmaceuticals & Biotechnology | 3.23% | 2.83% | -0.40% |
| 8 | Ajanta Pharma Limited ₹6.04 Cr |
Pharmaceuticals & Biotechnology | 5.20% | 4.83% | -0.37% |
| 9 | Fortis Healthcare Limited ₹1.37 Cr |
Healthcare Services | 1.28% | 1.10% | -0.18% |
| 10 | Cipla Limited ₹2.79 Cr |
Pharmaceuticals & Biotechnology | 2.39% | 2.23% | -0.16% |
31 stocks — Aug 2026
| # | Stock | Sector | Cap | Weight & Value |
|---|---|---|---|---|
| 1 |
₹13.57 Cr |
Pharmaceuticals & Biotechnology |
10.85%
|
|
| 2 |
₹13.43 Cr |
Pharmaceuticals & Biotechnology |
10.74%
|
|
| 3 |
₹11.09 Cr |
Pharmaceuticals & Biotechnology |
8.86%
|
|
| 4 |
₹6.21 Cr |
Healthcare Services |
4.96%
|
|
| 5 |
₹6.04 Cr |
Pharmaceuticals & Biotechnology |
4.83%
|
|
| 6 |
₹5.16 Cr |
Healthcare Services |
4.12%
|
|
| 7 |
₹5.09 Cr |
Pharmaceuticals & Biotechnology |
4.07%
|
|
| 8 |
₹5.02 Cr |
Pharmaceuticals & Biotechnology |
4.01%
|
|
| 9 |
₹4.92 Cr |
Healthcare Services |
3.93%
|
|
| 10 |
₹4.08 Cr |
Pharmaceuticals & Biotechnology |
3.26%
|
Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.
Found a discrepancy or have feedback? Contact Us — we read every message personally.